Effect of Weight-increasing Psychotropic Medications on Appetite Regulation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- PYY area under the curve
研究概览
简要总结
The purpose of this study is to evaluate changes in appetite-regulating hormones, body composition (weight, body fat%), and hunger ratings in persons early in treatment with one of four atypical antipsychotic medications (olanzapine, risperidone, ziprasidone, aripiprazole).
详细描述
Severe weight gain and glucose dysregulation are serious problems in patients treated with second-generation ('atypical') antipsychotics (SGA). These side effects frequently interfere with medication compliance and necessitate discontinuation of treatment. Although the causal mechanisms for weight and glucose dysregulation are not well understood, one promising area of investigation targets SGA-induced disturbances in appetite and in appetite-regulating hormones. Findings from our group (and others) demonstrate SGA treatment-related increases in fasting levels of the appetite-stimulating hormone, ghrelin, as well as increases in self-report hunger. This novel study will examine prospective changes in ghrelin and in the 'satiety-signaling' peptide YY (PYY) as measured before and after participants consume a standard mixed-macronutrient meal. Data are obtained at baseline (within 4 weeks of beginning medication), and again 2 months and 4 months later.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meets DSM IV criteria for a psychotic disorder (schizophrenia, schizophreniform, brief psychotic disorder, schizoaffective disorder), bipolar disorder, or major depression with psychotic features;
- •"Drug naïve" prior to most recent psychiatric diagnosis;
- •Currently prescribed one of four atypical antipsychotic medications: olanzapine, risperidone, ziprasidone, or aripiprazole;
- •Between the ages of 18 and 40, any race and either gender;
- •Not obese (BMI < 30 kg/m2) (fasting and postprandial ghrelin levels are altered in obesity);
- •Has negative histories for cardiovascular, metabolic, and endocrine disorders at screening;
- •Is willing and able to eat animal-derived foods; and
- •Is not exercising 3 or more times per week.
排除标准
- •Use of medications to treat metabolic and endocrine abnormalities, corticosteroids, over-the-counter appetite suppressants that contain phentermine or Sibutramine;
- •Active involvement with a weight loss program (i.e., Weight Watchers);
- •Serious or unstable medical illness which requires ongoing treatment with medication (this does not include hypertension);
- •At serious suicidal risk;
- •Current substance abuse or dependence;
- •For female subjects, pregnancy or nursing (because pregnancy may influence appetite and because the body composition procedure involves low level X-ray exposure).
- •Known history of mental retardation or dementia.
- •Children and adolescents under age 18 will be excluded owing to the inherent confounding effects of normal growth on body weight and appetite.
结局指标
主要结局
PYY area under the curve
时间窗: baseline, 2 and 4 months
ghrelin area under the curve
时间窗: baseline, 2 and 4 months
次要结局
- body composition(baseline, 2 and 4 months)
- subjective appetite ratings(baseline, 2 and 4 months)
- insulin area under the curve(baseline, 2 and 4 months)
- glucose area under the curve(baseline, 2 and 4 months)
研究者
Kimberly Brownley
Assistant Professor
University of North Carolina, Chapel Hill